Real-World Effectiveness and Risk Factors for Discontinuation of Ustekinumab in Ulcerative Colitis

Introduction: Ustekinumab (UST) has been approved for the treatment of moderate-to-severe ulcerative colitis (UC). Real-world data showing the effectiveness and safety of UST are necessary to confirm the results of clinical trials for applicability in daily clinical practice. Although some studies h...

Descripció completa

Dades bibliogràfiques

Autors principals:	Genta Uchida, Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, Eri Ishikawa, Kazuhiro Furukawa, Tadashi Iida, Yasuyuki Mizutani, Kentaro Yamao, Takuya Ishikawa, Yoji Ishizu, Takashi Honda, Masatoshi Ishigami, Hiroki Kawashima
Format:	Artigo
Idioma:	Inglês
Publicat:	Karger Publishers 2023-06-01
Col·lecció:	Inflammatory Intestinal Diseases
Matèries:	real-world evidence ustekinumab ulcerative colitis effectiveness risk factor
Accés en línia:	https://beta.karger.com/Article/FullText/531497
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!